quinoxalines has been researched along with Depression in 62 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.61) | 18.7374 |
| 1990's | 2 (3.23) | 18.2507 |
| 2000's | 7 (11.29) | 29.6817 |
| 2010's | 50 (80.65) | 24.3611 |
| 2020's | 2 (3.23) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, W; Huang, P; Jiang, L; Liu, J; Luo, L; Tang, X; Xu, N; Yi, W; Zhang, H; Zhou, J | 1 |
| Fujita, Y; Hashimoto, K; Iwata, M; Muneoka, K; Oda, Y; Shirayama, Y | 1 |
| Botanas, CJ; Bryan de la Peña, J; Chang Cho, M; Cheong, JH; Custodio, RJ; Joy Dela Peña, I; Kim, HI; Kim, HJ; Kim, M; Lee, YS; Woo, T | 1 |
| Bekker, A; Kang, S; Li, J; Ye, JH | 1 |
| Babinska, Z; Getachew, B; Luptak, M; Ruda-Kucerova, J; Tizabi, Y | 1 |
| Adell, A; Auberson, YP; Gordillo-Salas, M; Pilar-Cuéllar, F | 1 |
| Pałucha-Poniewiera, A; Pilc, A; Podkowa, K | 1 |
| Beenders, B; Bisulco, S; Budac, DP; Dantzer, R; Kelley, KW; Lee, AW; Smith, RA; Walker, AK | 1 |
| Brown, VL; Cinciripini, PM; Engelmann, JM; Karam-Hage, M; Lam, C; Minnix, JA; Robinson, JD; Versace, F; Wetter, DW | 1 |
| Bhatt, S; Devadoss, T; Jindal, A; Mahesh, R | 4 |
| Ebbert, JO; Frye, MA; Geske, JR; Lineberry, TW; Patten, CA; Prince, CA | 1 |
| Hays, JT | 1 |
| Gibbons, RD; Mann, JJ | 1 |
| Davies, NM; Gunnell, D; Martin, RM; Metcalfe, C; Thomas, KH; Windmeijer, F | 2 |
| Davies, SP | 1 |
| Ago, Y; Araki, R; Hasebe, S; Matsuda, T; Nishiyama, S; Oka, S; Takuma, K; Tanaka, T | 1 |
| Pałucha-Poniewiera, A; Pilc, A; Szewczyk, B | 1 |
| Fraser, K | 1 |
| Gupta, D; Kurhe, Y; Mahesh, R; Thangaraj, D | 1 |
| Gupta, D; Kurhe, Y; Radhakrishnan, M; Thangaraj, D | 1 |
| Kausch, O | 1 |
| Chaki, S; Koike, H | 1 |
| Devadoss, T; Gupta, D; Kurhe, Y; Mahesh, R | 1 |
| Gupta, D; Kanade, P; Kurhe, Y; Prabhakar, V; Radhakrishnan, M; Thangaraj, D | 1 |
| Devadoss, T; Kurhe, Y; Mahesh, R | 2 |
| Hooten, WM; Warner, DO | 1 |
| Joca, SR; Pereira, VS; Romano, A; Wegener, G | 1 |
| Gupta, D; Kurhe, Y; Radhakrishnan, M | 1 |
| Gunnell, D; Higgins, JP; Knipe, DW; Martin, RM; Thomas, KH | 1 |
| Chaki, S; Fukumoto, K; Iijima, M | 1 |
| Cao, J; Ding, ZY; Duan, TT; Jing, L; Mao, RR; Richter-Levin, G; Tan, JW; Tian, M; Xu, L; Yang, YX; Yuan, Q; Zhang, X; Zhou, QX; Zhu, YY | 1 |
| Kurosawa, N; Seki, K; Shimizu, K | 1 |
| Devadoss, T; Mahesh, R; Modak, N; Pandey, DK | 1 |
| McIntyre, RS | 1 |
| Coe, JW; Guanowsky, V; Mineur, YS; Picciotto, MR; Rollema, H; Seymour, PA; Shrikhande, A | 1 |
| Chapin, DS; Freeman, J; Guanowsky, V; Hajós, M; Hoffmann, WE; Horner, WE; Johnson, DE; Kozak, R; Majchrzak, MJ; McLean, S; Rollema, H; Seymour, PA; Williams, KE | 1 |
| Jiang, Z; Shang, J; Wang, W; Zhang, H; Zhang, L | 1 |
| Blendy, JA; Castellano, LM; Turner, JR | 1 |
| Pelle, AJ; Smolderen, KG | 1 |
| Bhatt, S; Devadoss, T; Mahesh, R; Pandey, DK; Yadav, SK | 1 |
| Chatterjee, A; Garza, D; Murphy, M; Riordan, HJ; Tseng, LJ | 1 |
| Chaki, S; Iijima, M; Koike, H | 1 |
| Balen, Gde O; Budni, J; Fernandes, SC; Freitas, AE; Moretti, M; Rodrigues, AL | 1 |
| Bhatt, S; Devadoss, T; Gautam, B; Gupta, D; Jindal, A; Mahesh, R; Pandey, D | 1 |
| Hayashi, K; Hori, H; Ikenouchi-Sugita, A; Katsuki, A; Nakamura, J; Umene-Nakano, W; Yoshii, C; Yoshimura, R | 1 |
| Furberg, CD; Glenmullen, J; Maltsberger, JT; Moore, TJ; Singh, S | 1 |
| Bechara, A; McNutt, A; Tranel, D | 1 |
| Aricioglu, F; Utkan, T; Yazir, Y | 1 |
| Andreas, S; Chenot, JF; Diebold, R; Mann, K; Peachey, S | 1 |
| Bhatt, S; Devadoss, T; Jindal, A; Kumar, B; Mahesh, R; Pandey, DK | 1 |
| Heiberg, IL; Rosenberg, R; Wegener, G | 1 |
| Barde, YA; Bonhoeffer, T; Korte, M; Rösch, H; Schweigreiter, R | 1 |
| Chen, G; Dow, ER; Du, J; Gould, TD; Manji, HK; O'Donnell, KC | 1 |
| Barturen, F; del Arco, C; García-Sevilla, JA; González, AM; Meana, JJ; Pascual, J; Pazos, A | 1 |
| Callado, LF; García-Sevilla, JA; Grijalba, B; Meana, JJ; Pazos, A; Sastre, M | 1 |
| Davies, SL; Hale, AS; Horton, RW; Katona, CL; Kelly, JS; Paykel, ES; Theodorou, AE; Yamaguchi, Y | 1 |
1 review(s) available for quinoxalines and Depression
| Article | Year |
|---|---|
Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis.
Topics: Aggression; Benzazepines; Depression; Humans; Mental Disorders; Quinoxalines; Risk Factors; Sleep Wake Disorders; Suicide; Suicide, Attempted; Tobacco Use Cessation Devices; Varenicline | 2015 |
5 trial(s) available for quinoxalines and Depression
| Article | Year |
|---|---|
Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal.
Topics: Adolescent; Adult; Affect; Aged; Benzazepines; Bupropion; Combined Modality Therapy; Counseling; Delayed-Action Preparations; Depression; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Treatment Outcome; Varenicline; Young Adult | 2013 |
A feasibility study of varenicline for smoking cessation in bipolar patients with subsyndromal depression.
Topics: Adult; Benzazepines; Bipolar Disorder; Depression; Feasibility Studies; Female; Humans; Male; Middle Aged; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Varenicline | 2013 |
Varenicline for opioid withdrawal in patients with chronic pain: a randomized, single-blinded, placebo controlled pilot trial.
Topics: Adult; Analgesics, Opioid; Benzazepines; Chronic Pain; Depression; Feasibility Studies; Female; Humans; Male; Middle Aged; Nicotinic Agonists; Opioid-Related Disorders; Pain Measurement; Pilot Projects; Quinoxalines; Single-Blind Method; Substance Withdrawal Syndrome; Treatment Outcome; Varenicline | 2015 |
A double-blind randomized placebo-controlled pilot study of neuropsychiatric adverse events in abstinent smokers treated with varenicline or placebo.
Topics: Adolescent; Adult; Aged; Aggression; Anxiety; Benzazepines; Depression; Double-Blind Method; Female; Humans; Irritable Mood; Male; Middle Aged; Nicotinic Agonists; Pilot Projects; Psychiatric Status Rating Scales; Quinoxalines; Smoking; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome; Varenicline | 2011 |
Effectiveness of varenicline as an aid to smoking cessation in primary care: an observational study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzazepines; Comorbidity; Depression; Female; Germany; Humans; Hypertension; Incidence; Lung Diseases, Obstructive; Male; Middle Aged; Nicotinic Agonists; Observation; Primary Health Care; Quinoxalines; Smoking Cessation; Tobacco Use Cessation Devices; Tobacco Use Disorder; Varenicline | 2013 |
56 other study(ies) available for quinoxalines and Depression
| Article | Year |
|---|---|
Involvement of Hippocampal AMPA Receptors in Electroacupuncture Attenuating Depressive-Like Behaviors and Regulating Synaptic Proteins in Rats Subjected to Chronic Unpredictable Mild Stress.
Topics: Animals; Behavior, Animal; Chronic Disease; Depression; Electroacupuncture; Excitatory Amino Acid Antagonists; Hippocampus; Male; Neuronal Plasticity; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Stress, Psychological; Synapses | 2020 |
Allopregnanolone induces antidepressant-like effects through BDNF-TrkB signaling independent from AMPA receptor activation in a rat learned helplessness model of depression.
Topics: Animals; Antidepressive Agents; Azepines; Behavior, Animal; Benzamides; Brain-Derived Neurotrophic Factor; Depression; Disease Models, Animal; Excitatory Amino Acid Antagonists; Helplessness, Learned; Male; Pregnanolone; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptor, trkB; Receptors, AMPA; Signal Transduction | 2020 |
Methoxetamine produces rapid and sustained antidepressant effects probably via glutamatergic and serotonergic mechanisms.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Cyclohexanones; Cyclohexylamines; Depression; Ketanserin; Male; Mice, Inbred ICR; Quinoxalines; Receptors, AMPA; Receptors, Serotonin; Serotonin Antagonists | 2017 |
Rescue of glutamate transport in the lateral habenula alleviates depression- and anxiety-like behaviors in ethanol-withdrawn rats.
Topics: Alcoholism; Amino Acid Transport System X-AG; Animals; Antidepressive Agents; Anxiety; Ceftriaxone; Central Nervous System Depressants; Depression; Ethanol; Excitatory Amino Acid Agonists; Excitatory Postsynaptic Potentials; Habenula; In Vitro Techniques; Kainic Acid; Male; Maze Learning; Nerve Tissue Proteins; Quinoxalines; Rats; Rats, Sprague-Dawley; Sodium Channel Blockers; Substance Withdrawal Syndrome; Swimming; Tetrodotoxin | 2018 |
Both ketamine and NBQX attenuate alcohol drinking in male Wistar rats.
Topics: Alcohol Drinking; Animals; Depression; Kainic Acid; Ketamine; Male; Quinoxalines; Rats, Wistar; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate | 2018 |
Signaling pathways responsible for the rapid antidepressant-like effects of a GluN2A-preferring NMDA receptor antagonist.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Depression; Male; Neuroglia; Neurons; Prefrontal Cortex; Quinoxalines; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Signal Transduction; Synapses; TOR Serine-Threonine Kinases | 2018 |
Role of AMPA receptor stimulation and TrkB signaling in the antidepressant-like effect of ketamine co-administered with a group II mGlu receptor antagonist, LY341495, in the forced swim test in rats.
Topics: Amino Acids; Animals; Antidepressive Agents; Azepines; Benzamides; Depression; Depressive Disorder; Excitatory Amino Acid Antagonists; Ketamine; Male; Prefrontal Cortex; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptor, trkB; Receptors, AMPA; Receptors, Metabotropic Glutamate; Signal Transduction; Xanthenes | 2019 |
NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL/6J mice.
Topics: Animals; Antidepressive Agents; Body Weight; Brain; Brain-Derived Neurotrophic Factor; Cytokines; Depression; Drug Administration Schedule; Drug Interactions; Eating; Excitatory Amino Acid Antagonists; Food Preferences; Immobility Response, Tonic; Indoleamine-Pyrrole 2,3,-Dioxygenase; Ketamine; Lipopolysaccharides; Liver; Male; Mice; Mice, Inbred C57BL; Motor Activity; Quinoxalines; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Signal Transduction | 2013 |
Anti-depressant like activity of N-n-butyl-3-methoxyquinoxaline-2-carboxamide (6o) a 5-HT3 receptor antagonist.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Depression; Fluoxetine; Guinea Pigs; Mice; Motor Activity; Olfactory Bulb; Paroxetine; Quinoxalines; Rats; Rats, Wistar; Serotonin 5-HT3 Receptor Antagonists; Swimming | 2013 |
Varenicline may reduce negative effect while aiding smoking cessation.
Topics: Benzazepines; Bupropion; Counseling; Depression; Female; Humans; Male; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Substance Withdrawal Syndrome | 2014 |
Varenicline, smoking cessation, and neuropsychiatric adverse events.
Topics: Adult; Aggression; Akathisia, Drug-Induced; Benzazepines; Bupropion; Depression; Female; Humans; Male; Mental Disorders; Nausea; Observational Studies as Topic; Psychomotor Agitation; Quinoxalines; Randomized Controlled Trials as Topic; Risk Factors; Smoking Cessation; Suicidal Ideation; Suicide, Attempted; Tobacco Use Cessation Devices; Treatment Outcome; Varenicline | 2013 |
Smoking cessation treatment and risk of depression, suicide, and self harm in the Clinical Practice Research Datalink: prospective cohort study.
Topics: Adolescent; Adult; Aged; Benzazepines; Bupropion; Cohort Studies; Depression; England; Female; Humans; Male; Middle Aged; Prospective Studies; Quinoxalines; Risk Assessment; Risk Factors; Self-Injurious Behavior; Smoking; Smoking Cessation; Suicide; Tobacco Use Cessation Devices; Varenicline; Young Adult | 2013 |
Still not clear that smoking cessation drugs do not cause psychiatric symptoms.
Topics: Benzazepines; Bupropion; Depression; Female; Humans; Male; Quinoxalines; Self-Injurious Behavior; Smoking; Smoking Cessation; Suicide; Tobacco Use Cessation Devices | 2013 |
Authors' reply to Davies.
Topics: Benzazepines; Bupropion; Depression; Female; Humans; Male; Quinoxalines; Self-Injurious Behavior; Smoking; Smoking Cessation; Suicide; Tobacco Use Cessation Devices | 2013 |
Involvement of prefrontal AMPA receptors in encounter stimulation-induced hyperactivity in isolation-reared mice.
Topics: Aggression; Animals; Animals, Outbred Strains; Cognition Disorders; Depression; Dopamine; Excitatory Amino Acid Antagonists; Hippocampus; Hyperkinesis; Male; Mice; Nucleus Accumbens; Prefrontal Cortex; Quinoxalines; Receptors, AMPA; Serotonin; Social Behavior; Social Isolation | 2014 |
Activation of the mTOR signaling pathway in the antidepressant-like activity of the mGlu5 antagonist MTEP and the mGlu7 agonist AMN082 in the FST in rats.
Topics: Animals; Antidepressive Agents; Benzhydryl Compounds; Depression; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Male; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Neuropsychological Tests; Prefrontal Cortex; Pyridines; Quinoxalines; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, AMPA; Receptors, Metabotropic Glutamate; Signal Transduction; Sirolimus; Swimming; Synapsins; Thiazoles; TOR Serine-Threonine Kinases | 2014 |
72nd annual meeting of the American Academy of Dermatology.
Topics: Antifungal Agents; Attention Deficit Disorder with Hyperactivity; Boron Compounds; Botulinum Toxins, Type A; Bridged Bicyclo Compounds, Heterocyclic; Brimonidine Tartrate; Depression; Dermatitis, Atopic; Food Hypersensitivity; Humans; Immunologic Factors; Ivermectin; Phosphodiesterase Inhibitors; Phototherapy; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinoxalines; Skin Diseases; Societies, Medical; Thalidomide; Triazoles; United States | 2014 |
Effect of (4a) a novel 5-HT3 receptor antagonist on chronic unpredictable mild stress induced depressive-like behavior in mice: an approach using behavioral tests battery.
Topics: Animals; Antidepressive Agents; Antioxidants; Behavior, Animal; Depression; Disease Models, Animal; Dose-Response Relationship, Drug; Lipid Peroxidation; Male; Mice; Piperazines; Quinoxalines; Serotonin 5-HT3 Receptor Antagonists; Stress, Psychological; Sucrose | 2015 |
Antidepressant and anti-anxiety like effects of 4i (N-(3-chloro-2-methylphenyl) quinoxalin-2-carboxamide), a novel 5-HT3 receptor antagonist in acute and chronic neurobehavioral rodent models.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Behavior, Animal; Depression; Dose-Response Relationship, Drug; Female; Guinea Pigs; Male; Mice; Motor Activity; Myenteric Plexus; Quinoxalines; Rats, Wistar; Serotonin; Serotonin 5-HT3 Receptor Antagonists | 2014 |
Treatment of depression in a former smoker with varenicline? A case report and discussion.
Topics: Benzazepines; Depression; Humans; Male; Middle Aged; Nicotinic Agonists; Quinoxalines; Smoking; Varenicline | 2014 |
Protective effects of a novel 5-HT3 receptor antagonist, N-n-butyl-3-methoxy quinoxaline-2-carboxamide (6o) against chronic unpredictable mild stress-induced behavioral changes and biochemical alterations.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Antioxidants; Chronic Disease; Depression; Male; Mice; Oxidative Stress; Quinoxalines; Serotonin 5-HT3 Receptor Antagonists; Stress, Psychological | 2014 |
Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats.
Topics: Adaptation, Psychological; Amino Acids; Animals; Antidepressive Agents; Depression; Disease Models, Animal; Excitatory Amino Acid Antagonists; Ketamine; Male; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Stress, Psychological; Swimming; Time Factors; Xanthenes | 2014 |
QCM-4, a serotonergic type 3 receptor modulator attenuates depression co-morbid with obesity in mice: an approach based on behavioral and biochemical investigations.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Blood Glucose; Blood Proteins; Cholesterol; Depression; Diet, High-Fat; Hypoglycemic Agents; Male; Mice; Motor Activity; Obesity; Quinoxalines; Serotonin 5-HT3 Receptor Antagonists; Stress, Psychological; Triglycerides | 2014 |
Neuropharmacological effect of novel 5-HT3 receptor antagonist, N-n-propyl-3-ethoxyquinoxaline-2-carboxamide (6n) on chronic unpredictable mild stress-induced molecular and cellular response: Behavioural and biochemical evidences.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain; Catalase; Depression; Disease Models, Animal; Dose-Response Relationship, Drug; Fluoxetine; Glutathione; Lipid Peroxidation; Male; Mice; Motor Activity; Quinoxalines; Serotonin 5-HT3 Receptor Antagonists; Superoxide Dismutase; Swimming | 2014 |
Antidepressant-like effects of a novel 5-HT3 receptor antagonist 6z in acute and chronic murine models of depression.
Topics: Acute Disease; Animals; Antidepressive Agents; Antioxidants; Behavior, Animal; Benzothiazoles; Biomarkers; Brain; Chronic Disease; Corticosterone; Depression; Disease Models, Animal; Dose-Response Relationship, Drug; Feeding Behavior; Female; Fluoxetine; Guinea Pigs; Hypothalamo-Hypophyseal System; Ileum; Lipid Peroxidation; Male; Mice; Motor Activity; Oxidative Stress; Pituitary-Adrenal System; Quinoxalines; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Antagonists | 2014 |
QCM-4, a 5-HT₃ receptor antagonist ameliorates plasma HPA axis hyperactivity, leptin resistance and brain oxidative stress in depression and anxiety-like behavior in obese mice.
Topics: Adrenal Cortex Hormones; Animal Feed; Animals; Antidepressive Agents; Anxiety; Brain; Depression; Dietary Fats; Glutathione; Hypothalamo-Hypophyseal System; Leptin; Male; Malondialdehyde; Maze Learning; Mice; Mice, Obese; Oxidative Stress; Quinoxalines; Serotonin 5-HT3 Receptor Antagonists; Sucrose; Swimming | 2015 |
Antidepressant-like effects induced by NMDA receptor blockade and NO synthesis inhibition in the ventral medial prefrontal cortex of rats exposed to the forced swim test.
Topics: Animals; Antidepressive Agents; Depression; Dose-Response Relationship, Drug; Isoquinolines; Male; Nitric Oxide; Nitric Oxide Synthase Type I; Prefrontal Cortex; Quinoxalines; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Swimming | 2015 |
Effect of a novel 5-HT3 receptor antagonist 4i, in corticosterone-induced depression-like behavior and oxidative stress in mice.
Topics: Animals; Behavior, Animal; Catalase; Corticosterone; Depression; Glutathione; Hypothalamus; Lipid Peroxidation; Male; Mice; Motor Activity; Nitrites; Oxidative Stress; Pituitary-Adrenal System; Quinoxalines; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Antagonists; Swimming | 2015 |
The Antidepressant Effects of an mGlu2/3 Receptor Antagonist and Ketamine Require AMPA Receptor Stimulation in the mPFC and Subsequent Activation of the 5-HT Neurons in the DRN.
Topics: Amino Acids; Animals; Antidepressive Agents; Depression; Dorsal Raphe Nucleus; Fenclonine; Ketamine; Male; Mice; Mice, Inbred C57BL; Neural Pathways; Prefrontal Cortex; Quinoxalines; Receptors, AMPA; Receptors, Metabotropic Glutamate; Serotonergic Neurons; Xanthenes | 2016 |
Despair-associated memory requires a slow-onset CA1 long-term potentiation with unique underlying mechanisms.
Topics: Animals; CA1 Region, Hippocampal; Corticosterone; Depression; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Immunoblotting; Ketamine; Long-Term Potentiation; Male; Memory; Mineralocorticoid Receptor Antagonists; Phosphorylation; Quinoxalines; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, Glucocorticoid; Receptors, N-Methyl-D-Aspartate; Spironolactone; Stress, Psychological; Swimming | 2015 |
The role of the AMPA receptor and 5-HT(3) receptor on aggressive behavior and depressive-like symptoms in chronic social isolation-reared mice.
Topics: Aggression; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Amygdala; Animals; Depression; Food Preferences; Glutamate Decarboxylase; Hypothalamus; Injections, Intraperitoneal; Male; Mice; Microinjections; Motor Activity; Neurons; Ondansetron; Piperidines; Quinoxalines; Receptors, AMPA; Receptors, Serotonin, 5-HT3; Social Isolation | 2016 |
Neuropharmacological and neurochemical evaluation of N-n-propyl-3-ethoxyquinoxaline-2-carboxamide (6n): a novel serotonergic 5-HT3 receptor antagonist for co-morbid antidepressant- and anxiolytic-like potential using traumatic brain injury model in rats.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Brain Injuries, Traumatic; Depression; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Maze Learning; Quinoxalines; Rats; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Antagonists | 2017 |
Novel 5-HT
Topics: Animals; Anxiety; Brain Chemistry; Brain-Derived Neurotrophic Factor; Depression; Diet, High-Fat; Hippocampus; Insulin Resistance; Male; Mice; Motor Activity; Obesity; Quinoxalines; Serotonin; Serotonin 5-HT3 Receptor Antagonists; Swimming; Tumor Suppressor Protein p53 | 2017 |
Antidepressant & anxiolytic activities of N-(pyridin-3-yl) quinoxalin-2-carboxamide: A novel serotonin type 3 receptor antagonist in behavioural animal models.
Topics: Animals; Antidepressive Agents; Anxiety; Depression; Depressive Disorder; Disease Models, Animal; Feeding and Eating Disorders; Male; Mice; Motor Activity; Obsessive-Compulsive Disorder; Quinoxalines; Rats; Rats, Wistar; Receptors, Serotonin; Schizophrenia; Serotonin; Serotonin 5-HT3 Receptor Antagonists | 2016 |
Varenicline: depression and suicide. Nicotine is a safer option.
Topics: Benzazepines; Depression; Humans; Nicotine; Quinoxalines; Smoking Cessation; Suicide | 2008 |
Varenicline and suicidality: a new era in medication safety surveillance.
Topics: Adverse Drug Reaction Reporting Systems; Benzazepines; Depression; Drug Labeling; Humans; Psychomotor Agitation; Quinoxalines; Smoking Cessation; Suicide; Suicide Prevention; Varenicline | 2008 |
Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect.
Topics: Animals; Antidepressive Agents; Benzazepines; Depression; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Nicotinic Agonists; Quinoxalines; Receptors, Nicotinic; Selective Serotonin Reuptake Inhibitors; Sertraline; Swimming; Varenicline | 2009 |
Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition.
Topics: Affect; Alcohol Drinking; Animals; Attention; Benzazepines; Cerebral Cortex; Cognition; Depression; Drug Partial Agonism; Hippocampus; Humans; Male; Mice; Mice, Inbred C57BL; Neurotransmitter Agents; Nicotinic Agonists; Quinoxalines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Nicotinic; Recognition, Psychology; Reflex, Startle; Reward; Tobacco Use Disorder; Varenicline | 2009 |
Differential involvement of 5-HT(1A) and 5-HT(1B/1D) receptors in human interferon-alpha-induced immobility in the mouse forced swimming test.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Buspirone; Depression; Fluoxetine; Interferon-alpha; Male; Mice; Mice, Inbred ICR; Motor Activity; Oxadiazoles; Piperazines; Pyridines; Quinoxalines; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, 5-HT1D; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT1 Receptor Antagonists; Serotonin Antagonists; Serotonin Receptor Agonists; Swimming | 2010 |
Nicotinic partial agonists varenicline and sazetidine-A have differential effects on affective behavior.
Topics: Animals; Anxiety; Azetidines; Behavior, Animal; Benzazepines; Chimera; Depression; Drug Partial Agonism; Male; Mice; Mood Disorders; Nicotine; Nicotinic Agonists; Pyridines; Quinoxalines; Varenicline | 2010 |
Letter by Smolderen and Pelle regarding article, "Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial".
Topics: Benzazepines; Cardiovascular Diseases; Depression; Humans; Nicotinic Agonists; Patient Selection; Quinoxalines; Randomized Controlled Trials as Topic; Risk Factors; Smoking; Smoking Cessation; Varenicline | 2010 |
Design, synthesis and structure-activity relationship of novel quinoxalin-2-carboxamides as 5-HT3 receptor antagonists for the management of depression.
Topics: Amides; Animals; Depression; Drug Design; Guinea Pigs; Mice; Quinoxalines; Receptors, Serotonin, 5-HT3; Serotonin Antagonists; Spectrometry, Mass, Electrospray Ionization; Structure-Activity Relationship | 2010 |
Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Depression; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Electroshock; Excitatory Amino Acid Antagonists; Helplessness, Learned; Hindlimb Suspension; Ketamine; Male; Mice; Mice, Inbred ICR; Motor Activity; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Time Factors | 2011 |
Involvement of nitric oxide-cGMP pathway in the antidepressant-like effect of ascorbic acid in the tail suspension test.
Topics: Animals; Antidepressive Agents; Arginine; Ascorbic Acid; Cyclic GMP; Depression; Disease Models, Animal; Dizocilpine Maleate; Enzyme Inhibitors; Exploratory Behavior; Female; Hindlimb Suspension; Indazoles; Mice; N-Methylaspartate; Nitric Oxide; Oxadiazoles; Piperazines; Purines; Quinoxalines; Signal Transduction; Sildenafil Citrate; Sulfones | 2011 |
Anti-depressant-like activity of a novel serotonin type-3 (5-HT3) receptor antagonist in rodent models of depression.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Hindlimb Suspension; Male; Mice; Molecular Structure; Motor Activity; Quinoxalines; Rats; Rats, Wistar; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Antagonists; Swimming | 2011 |
Plasma levels of metabolites of catecholamine in nicotine-dependent patients treated with varenicline.
Topics: Adult; Benzazepines; Catecholamines; Depression; Female; Homovanillic Acid; Humans; Male; Methoxyhydroxyphenylglycol; Middle Aged; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2012 |
Suicidal behavior and depression in smoking cessation treatments.
Topics: Adult; Benzazepines; Bupropion; Depression; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Suicide; Varenicline | 2011 |
Smoking cessation after brain damage does not lead to increased depression: implications for understanding the psychiatric complications of varenicline.
Topics: Adult; Benzazepines; Brain Injury, Chronic; Depression; Female; Humans; Male; Middle Aged; MMPI; Nicotinic Agonists; Psychiatric Status Rating Scales; Quinoxalines; Smoking; Smoking Cessation; Varenicline | 2012 |
Inhibition of neuronal nitric oxide synthase and soluble guanylate cyclase prevents depression-like behaviour in rats exposed to chronic unpredictable mild stress.
Topics: Animals; Antidepressive Agents; Cyclic GMP; Depression; Enzyme Inhibitors; Guanylate Cyclase; Hippocampus; Indazoles; Male; Nitric Oxide Synthase Type I; Oxadiazoles; Quinoxalines; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Soluble Guanylyl Cyclase; Stress, Psychological; Swimming | 2012 |
Antidepressant and anxiolytic-like effects of 4n, a novel 5-HT3 receptor antagonist using behaviour based rodent models.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Depression; Emotions; Mice; Olfactory Bulb; Ondansetron; Paroxetine; Photoperiod; Quinoxalines; Rats; Rats, Wistar; Reserpine; Serotonin 5-HT3 Receptor Antagonists; Swimming | 2012 |
Reduction of cGMP and nitric oxide has antidepressant-like effects in the forced swimming test in rats.
Topics: Animals; Antidepressive Agents, Tricyclic; Arginine; Cyclic GMP; Depression; Dimethyl Sulfoxide; Enzyme Inhibitors; Guanylate Cyclase; Imipramine; Indazoles; Male; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Oxadiazoles; Quinoxalines; Rats; Rats, Sprague-Dawley; Swimming | 2002 |
The neurotrophin receptor p75NTR modulates long-term depression and regulates the expression of AMPA receptor subunits in the hippocampus.
Topics: Animals; Blotting, Western; Depression; Excitatory Postsynaptic Potentials; Gene Expression Regulation; Hippocampus; Mice; Mice, Inbred C57BL; Mice, Knockout; Mutation; Neuronal Plasticity; Quinoxalines; Receptor, Nerve Growth Factor; Receptors, AMPA; Receptors, Nerve Growth Factor; Signal Transduction; Synaptic Transmission; Valine | 2005 |
Involvement of AMPA receptors in the antidepressant-like effects of lithium in the mouse tail suspension test and forced swim test.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Benzodiazepines; Brain; Depression; Disease Models, Animal; Drug Administration Routes; Excitatory Amino Acid Antagonists; Exploratory Behavior; Hindlimb Suspension; Injections, Intraventricular; Lithium Compounds; Mice; Mice, Inbred C57BL; Protein Transport; Quinoxalines; Receptors, AMPA; Swimming; Time Factors | 2008 |
Autoradiographic demonstration of increased alpha 2-adrenoceptor agonist binding sites in the hippocampus and frontal cortex of depressed suicide victims.
Topics: Adrenergic alpha-Agonists; Adult; Autoradiography; Binding Sites; Brain Chemistry; Brimonidine Tartrate; Cerebral Cortex; Depression; Female; Hippocampus; Humans; Male; Middle Aged; Quinoxalines; Receptors, Adrenergic, alpha-2; Suicide | 1994 |
Selective increase of alpha2A-adrenoceptor agonist binding sites in brains of depressed suicide victims.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adult; Autoradiography; Binding, Competitive; Brain Chemistry; Brimonidine Tartrate; Cell Membrane; Clonidine; Depression; Female; Frontal Lobe; Humans; Idazoxan; Male; Middle Aged; Quinoxalines; Receptors, Adrenergic, alpha-2; Suicide; Tritium | 1998 |
Platelet high affinity adrenoceptor binding sites labelled with the agonist [3H]UK-14,304, in depressed patients and matched controls.
Topics: Adult; Blood Platelets; Brimonidine Tartrate; Clonidine; Depression; Female; Humans; Kinetics; Male; Middle Aged; Quinoxalines; Receptors, Adrenergic, alpha | 1986 |